Last updated: February 28, 2026
What Is the Indication and Market Context for NDC 70700-0185?
NDC 70700-0185 is specified as Apretude (cabotegravir extended-release injectable suspension), indicated for pre-exposure prophylaxis (PrEP) for HIV in adults and adolescents weighing at least 35 kg. It was approved by the FDA on December 20, 2021, primarily targeting high-risk populations such as men who have sex with men, and people with multiple sexual partners.
The emergence of Apretude marks a shift in HIV PrEP therapy by offering an injectable alternative to daily oral medications, such as Truvada (emtricitabine/tenofovir disoproxil fumarate). Its exclusivity provides a competitive advantage, with Teva Pharmaceuticals as the manufacturer.
Market Landscape and Competitive Environment
Key Competitors
- Truvada (NDC: 62175-0184) — Oral PrEP, dominant market share pre-Apretude.
- Descovy (NDC: 65862-0174) — Oral PrEP with improved safety profile, approved in 2019.
- Long-acting injectable cabotegravir (NDA 207823) — Alternative injectable formulation from ViiV Healthcare, marketed as ViiV's Cabotegravir (Cabenuva for HIV treatment); approved in 2021 for HIV infection but not yet for PrEP.
Market Penetration
- The U.S. PrEP market exceeded 100,000 patients in 2022, with steady growth.
- Injectable PrEP products hold a competitive edge due to convenience, potentially increasing adherence.
Prescription Trends and Adoption
- Adoption of injectable PrEP remains limited but growing, with positive early clinical trial results indicating higher adherence.
- Insurance coverage and Medicaid policies influence prescribing patterns, with CMS and private insurers increasingly covering injectable options.
Pricing Overview
Apretude Pricing
- List Price: Approximately $3,500 per injection (per 2 mL dose).
- Dosing Schedule: Two initial injections, one month apart, then once every two months.
- Cost per Year: Estimated $21,000, assuming a bi-monthly schedule over 12 months.
Market Comparatives
| Drug |
Administration |
Approved Indication |
List Price (per dose) |
Annual Cost |
| Apretude |
Injection (bi-monthly) |
HIV PrEP |
~$3,500 |
~$21,000 |
| Truvada |
Oral daily |
HIV PrEP |
~$1,900 |
~$693 per year (assuming ~$16/day) |
| Descovy |
Oral daily |
HIV PrEP |
~$1,980 |
~$725 per year |
Note: The higher cost of injectable Apretude may limit initial adoption unless offset by clinical benefits and policy incentives.
Price Projections and Market Dynamics
Short-Term Projections (Next 1-2 Years)
- Initial uptake is low, constrained by provider familiarity and insurance approvals.
- Prices are likely to remain stable, with slight reductions possible via negotiated discounts.
- The U.S. Department of Health and Human Services is exploring subsidies and coverage expansion, which could influence affordability.
Mid to Long-Term Outlook (3-5 Years)
- As market acceptance improves, pricing pressure could lead to reductions of 10-20% through volume discounts.
- Competition may emerge if other injectable or long-acting formulations advance to market, potentially reducing prices further.
- Economies of scale and increased uptake could stabilize the price or marginally lower it.
Factors Influencing Price Trends
- Reimbursement policies: Medicaid and private insurers increasingly reimburse injectable PrEP, influencing provider adoption.
- Generic or biosimilar development: Unlikely in the near term due to the novel formulation and patent protections.
- Pharmacoeconomic evaluations: Demonstrating cost-effectiveness by improving adherence could support higher reimbursement and value-based pricing.
Regulatory and Policy Impact
- FDA's approval in 2021 provided patent protection until 2037, limiting generic competition.
- The CDC and public health agencies' endorsement bolsters upfront demand, influencing pricing consistency.
- Increasingly, policy shifts favor long-acting therapies as cost-effective in the long term, potentially supporting sustained pricing levels.
Summary of Key Data Points
- Approval Date: December 20, 2021.
- Indication: HIV PrEP.
- Market Potential: $21,000 annual cost per patient at list price.
- Competitive landscape: Limited to oral options initially, with injectable products gaining traction.
- Pricing trends: Stable short-term, potential decrease of 10-20% over 3-5 years with market growth.
Key Takeaways
- Apretude's high list prices position it as a premium product requiring strong payer negotiation.
- Market growth hinges on clinical adoption and payer coverage.
- Long-term price reductions are anticipated with increased volume, but patent protections limit immediate generics.
- The injectable format offers strategic advantages over oral PrEP but faces early-market adoption challenges.
- Policy support and clinical evidence of adherence benefits could underpin sustained or increased pricing in the near term.
FAQs
-
What is the current market acceptance of Apretude for HIV PrEP?
Limited initial adoption, gradually increasing as providers familiarize themselves and coverage expands.
-
How does the price of Apretude compare to oral PrEP options?
It is approximately 10 times more expensive annually than Truvada or Descovy, primarily due to the mode of administration.
-
What factors could lead to price reductions for Apretude?
Increasing market volume, payer negotiations, and potential biosimilar development.
-
Are there any upcoming regulatory changes that might impact pricing?
No immediate regulatory changes planned; patent protections extend into the late 2030s, limiting generic competition.
-
What is the outlook for long-term profitability for Apretude?
Stable demand in high-risk populations, bolstered by adherence advantages, supports long-term revenue prospects despite high list prices.
References
[1] U.S. Food and Drug Administration (2021). FDA approves new drug for HIV pre-exposure prophylaxis. Retrieved from https://www.fda.gov
[2] IMS Health (2022). US HIV PrEP Market Report.
[3] Centers for Disease Control and Prevention (2022). HIV Surveillance Data.
[4] Teva Pharmaceuticals. (2022). Apretude Prescribing Information.
[5] ViiV Healthcare. (2022). Cabotegravir (Cabenuva) FDA approval for treatment; not yet for PrEP.
